Status: New
| Name & address of the Laboratory/Organization | CSIR-Institute of Himalayan Bioresource Technology (IHBT) | |
| Website address | www.ihbt.res.in | |
| Affiliated to which Department/Ministry | Council of Scientific and Industrial Research (CSIR) | |
| CSR Registration Number | CSR00017422 | |
| Registration under 12A | ||
| Registration under 80G | ||
| Name of the CSR Nodal | Dr. Sukhjinder Singh | |
| Contact information of CSR Nodal | 9418143470, sukhjinder@ihbt.res.in | |
| Principal Investigator | Dr. Narendra Vijay Tirpude , narendra@ihbt.res.in | |
| Co- Principal Investigator (Co-PI) | Dr. Ankit Saneja, ankitsaneja@ihbt.res.in | |
| Objective on the basis of need | In vitro screening of potential natural bioactives for their anti-asthmatic activity. Development of formulations and their drug delivery systems In vivo validation developed formulations for allergic asthma in animal models |
| Executive summary of the proposed project (In 250 words) | India has 18% of the global population and an increasing burden of chronic respiratory diseases. Asthma was responsible for 20·0% of the chronic respiratory disease disability-adjusted life-years in India in 2016. Though the number of patients with respiratory diseases is very large, alternate medication for the treatment of these diseases is limited. Thus, this project is aimed at developing low-cost, natural, safe, therapeutic integrative therapy for the treatment of allergic asthma. Novelty: The proposal is targeted at validating the efficacy of selected bioactives for allergic asthma. The study aims to establish potential lead molecules for fast-track product formulation and relevant delivery systems. Efficacy evaluation of the developed formulations and their delivery systems will also serve as validation of traditional knowledge in treating asthma. Objectives: 1. In vitro screening of potential natural bioactives for their anti-asthmatic activity. 2. Development of formulations and their drug delivery systems 3. In vivo validation developed formulations for mitigating allergic asthma in animal models. Methods: Development of formulations: FSSAI and WHO-approved supplements/ base ingredients will be used for product development. In vitro analysis: Cell (alveolar macrophages) viability evaluation and In-vitro screening on allergen-exposed macrophages by evaluating Th2 cytokines/ Th1 cytokines levels In vivo safety evaluation to delineate the dose In vivo efficacy evaluation: Bioactives and their formulations will be screened for their anti-asthmatic potential. |
| Technology Readiness Level (If not a new project but an advancement of existing know how) | TRL1 |
| Outomes or Deliverables | Development of cheap alternative products for allergic asthma • Validation of the role of selected bioactives as anti-alarmins • Preclinical evaluation of developed formulations |
| Project aligned with which most relevant UN SDGs | Goal 3 - Good Health & Well-Being |
| Duration (In years) | 3 years |
| Expected Impact | The proposal would augment the traditional knowledge by validating role of natural bioactives in mitigating pathologies of allergic asthma. • Further, safety assessment and bioactivity guided screening of bioactive anti-alarmins is proposed to substantiate the traditional knowledge • In order to appeal to the masses, it is proposed that outcome of the project will be able to cater the entire spectrum of audiences including the Nutrition and Health care industry |
| Implementation model (self- implemented/ outsourced partnership) | outsourced partnership |
| Total Budget (Recurring +Non-Recurring Expenses) | 82,02,488.72 |